News summary

In vivo engineering of CAR natural killer cells for immunotherapy using ligand-directed lipid nanoparticles

Source: Nature - Biotechnology • Published: 13 Oct 2026, 00:00

Summarized by Masters of Longevity from Nature - Biotechnology.

Demonstration of ligand-directed lipid nanoparticles that program natural killer cells in vivo to express CARs and enhance antitumor and autoimmune therapies.

In vivo engineering of CAR natural killer cells for immunotherapy using ligand-directed lipid nanoparticles
Key Takeaways
  • Engineered NK-targeted LNPs achieved roughly 80% NK cell transfection rates in mice with minimal off-target delivery.
  • Systemic delivery of CAR mRNA via these LNPs generated CAR NK cells that fully depleted circulating B cells in healthy mice.
  • CAR NK cells produced in vivo eliminated autoreactive T cells in an autoimmune hepatitis model and regressed humanized hematologic tumors.
Read the full article at Nature - Biotechnology ↗

Continue exploring

Recommended MoL Picks

MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickNucleotides and Longevity: Is the Evidence Ready?They help build DNA and keep cells working. Early human studies make nucleotide supplements interesting—but leave important questions about healthy ageing unanswered. Yet.MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.